Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ambrisentan in IPF and Pulmonary Hypertension
NCT00879229Phase 3Terminated
- Sponsor
- Gilead Sciences
- Start
- Jul 2009
- Primary completion
- Feb 2011
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of ambrisentan in idiopathic pulmonary fibrosis (IPF), pulmonary hypertension (PH), sponsored by Gilead Sciences. Started Jul 2009; status: terminated.
02
Drugs
ambrisentan
03
Conditions
idiopathic pulmonary fibrosis (IPF)pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT00879229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00879229.